Bacterial pneumonia is a relevant cause of morbidity and mortality in children especially in developing countries where approximately 4 million children under 5 years of age die of this disease every year. 1 The aetiology of childhood pneumonia has been considered a critical issue in clinical practice and particularly for research purposes. Only a small proportion of cases yield positive bacterial isolation in blood culture specimens, since microbiological diagnostic tests lack sensitivity. Furthermore, in many developing areas, the widespread use of antibiotics prior to health service access is a common practice decreasing the odds of recovering bacteria.
Haemophilus influenzae type b (Hib) causes a wide variety of clinical manifestations and is a leading agent of invasive infections among children, such as meningitis, pneumonia, epiglottitis, septicaemia, osteomyelitis, and arthritis. In developing regions, pneumonia is the most important manifestation of Hib while meningitis is the major invasive Hib disease in industrialized countries. [2] [3] [4] In a recent systematic review of H. influenzae based on laboratory surveillance data in Latin America over the last 10 years, type b was predominant among 5362 H. influenzae isolates of invasive diseases, mainly in children under 5 years old. 5 The burden of Hib pneumonia in children has been proven by lung aspiration in large studies conducted in Africa and Asia and in case series in Latin America, making non-bacteraemic pneumonia probably the principal Hib disease worldwide. [6] [7] [8] The evidence base of the efficacy of Hib conjugate vaccine for the prevention of pneumonia in infants comes from the large randomized trial of Gambia. 9 In Chile, a post-license Hib vaccination study showed 80% of effectiveness against Hib bacteraemic pneumonia. 10 The impact of the Hib vaccine on pneumonia after the vaccine introduction was also assessed by linking a retrospective evaluation of hospitalization for pneumonia with the previous dataset of the Hib vaccine effectiveness study. 11 Conjugate Hib vaccine has been available for more than a decade, and it is estimated that close to 20% of the world's children will have this vaccine included in the immunization schedule. In the Americas, more than 95% of the children born in the year 2002 will have Hib vaccine as part of their regular immunization schedule. 12 The cost of the vaccine has hampered mass scale vaccine implementation, especially in other non-industrialized countries. 13, 14 Meningitis prevention has been the main target for the vaccine and it has been highly efficacious in reducing H. influenzae type b meningitis. 15 In 1999, the Hib conjugate vaccine was introduced into the Infant Immunization Program as routine in Brazil. In a highly urbanized city in Central Brazil, a prospective population-based surveillance of pneumonia among children was initiated immediately after Hib vaccine implementation. Taking advantage of this ongoing surveillance we designed a matched case-control study to evaluate the effectiveness of Hib vaccination in the reduction of radiologically confirmed pneumonia among children.
Patients and Methods

Study setting
The investigation was launched in May 2000, in the municipality of Goiânia, Central Brazil, with a predominantly urban population of 1 090 581 inhabitants. Children less than 5 years old account for 105 105 inhabitants and the infant mortality rate is estimated as 16 per 1000 live births. 16 H. influenzae conjugate CRM 197 vaccine (HbOC; HibTITER, WyethLederle) was introduced in July 1999. During the study period the target population for Hib conjugate vaccine was children aged 2-24 months. The vaccination was scheduled in three doses without booster at 2, 4, and 6 months of age, concurrently with diphtheria, tetanus, and pertussis (DPT) vaccine. For children with an incomplete schedule (0-2 doses) in the first year of life, there was a recommendation for a single Hib vaccine dose between 1-2 years of age.
Population-based surveillance of pneumonia
This prospective surveillance to detect new cases of communityacquired pneumonia is part of a major project to assess the burden of H. influenzae and Streptococcus pneumoniae infection in childhood. 17 This network comprised 20 paediatric hospitals, responsible for almost 90% of the pneumonia admission in the city. At outpatient level, children with cough or difficulty breathing were sent to chest X-ray if they presented one of the following signs: 1 (1) breathing Ͼ40/minute and no chest indrawing; or (2) chest indrawing and/or any danger sign (unable to feed, vomiting, cyanosis, lethargy, or unconsciousness). The radiographs were initially examined by the paediatricians and, according to their interpretation, children with an X-ray compatible with bacterial pneumonia ('potential cases') were referred for hospitalization regardless of disease severity (mild, moderate, or severe) ( Figure 1 ). In our city all requests for hospital admission must be authorized by a Call Center System (Hospital Admission Electronic Information System) located at the Secretariat of Health of Goiânia, where the research team closely monitored and recorded the baseline data of all the hospitalized pneumonia cases on a daily basis. At hospital admission the radiographs of all 'potential cases' were photographed with digital cameras (Mavica® FD90) following technical procedures previously defined. 18 Soon after a child's hospitalization, two radiologists, allocated to the project, reviewed independently all the digital photos. They were trained to use the standard World Health Organization (WHO) criteria for interpretation of radiographs and diagnosis of pneumonia. 19 There was 85% of concordance on the pneumonia pattern between the two radiologists and the remaining discordant readings (15%) were reviewed by a senior radiologist. Coded forms were used to record the location, type of the infiltrates, and presence of atelectasis, cavitations/abscess, airways and/ or airspace disease, hyperinflation, and pleural effusion. The features examined focused on alveolar consolidation and interstitial infiltrate with or without hyperinflation. Cases with both alveolar and interstitial patterns were coded as mixed. For the purpose of this study, a pneumonia case was defined by the presence of alveolar consolidation and/or pleural effusion and/ or mixed pattern, herein called radiologically definite pneumonia. The clinical case definition for children with radiologically definite pneumonia was established according to the signs present during the clinical assessment at the time of the hospital admission and followed the WHO guidelines. 1, 20 In addition to cough and difficulty breathing (mild pneumonia) children with no chest indrawing and fast breathing were considered as moderate pneumonia while those concurrently with chest indrawing or danger signs (unable to drink or breastfeed, vomiting, convulsions, lethargy, or unconsciousness) were considered as severe pneumonia.
Selection of participants for the case-control study
All children up to 2 years old diagnosed as community-acquired pneumonia at the outpatient level, flagged by the ongoing surveillance system and refereed to hospitals, were considered potential cases. To be included in the study, the child had to have pneumonia confirmed radiologically, according to the WHO criteria 19 and to reside in Goiânia. In our setting, chest X-rays are routinely taken at the paediatric ambulatory clinic when pneumonia is suspected and children diagnosed as having pneumonia by the paediatricians are referred for hospitalization, irrespective of the severity. Findings on clinical examination, course and outcome of illness were recorded on a standard form for all patients enrolled. Each case had a house visit just after the hospital discharge to confirm the residential address and to concurrently select controls. Criteria for selecting controls were children without previous episodes of hospitalized pneumonia. During the household visit, the mothers were interviewed about history of hospitalization including date, hospital name, and cause of hospital admission. The information on absence of hospitalization for pneumonia was checked in the Call Center System file to confirm that controls had not had any hospitalized pneumonia. Two controls were identified among children from the same neighbourhood and matched by age stratum (±4 months). Controls were selected using the confirmed address of the case as the starting point. Field researchers were instructed to search for potential controls as close as possible to the case location, beginning at the same block as the household of the pneumonia case, and subsequently searching for the nearest block until a matched control was identified. In all, 306 cases (71.0%) had matched controls selected in the same census block as the cases, within a mean distance of 170 m of the household of the pneumonia case. For the remaining cases, the matched controls lived within a mean distance of 716 m of the case. All households had equal access to health-related and other facilities.
The households of cases and controls were visited and parents were interviewed to obtain information on socioeconomic data, history of previous illness, and potential confounding variables. Day-care attendance meant full time (i.e. 8 hours/day), therefore there was no difference between length of time of HAEMOPHILUS INFLUENZAE B VACCINE AND CHILDHOOD PNEUMONIA 175 Figure 1 day-care attendance between cases and controls. Since this case-control study was matched by neighbourhood, type of daycare attendance did not differ between cases and controls. The institutions in charge of day-care attendance are public and the child admission policy gives priority to those resident in the vicinity. Hib conjugate vaccination status was obtained by checking the immunization card during the house visits. The vaccination history of controls was considered until the age at which the matched case developed disease. The research was approved by the Regional and National Ethics Committee. The field investigators outlined the study to parents or guardians of the participants, to obtain the written informed consent to participate. No refusal was reported.
Data analysis
Data were analysed using the statistical package EpiInfo™ 2000 (Version 1.1.2). 21 The required sample size was estimated as 400 cases and 800 controls, assuming an expected reduction of less than 30% in pneumonia between vaccinated and unvaccinated group with 80% power, ratio of controls per case of 2:1, and 5% significance level (two-tailed) for a vaccination coverage of 70%. Categorical data were compared using 2 test or Fisher's exact test and continuous covariates by using the Student's t test. Conditional logistic regression (CLR) was performed to assess the odds ratio (OR) with respective 95% CI of the independent effect of conjugate vaccination on reduction of radiologically definite pneumonia (EGRET software, version 0.19.6). Variables statistically associated with pneumonia in univariate analysis were adjusted for in the multivariate model. Although controls were matched to cases by age stratum, age as a continuous variable entered into the final CLR model since it was regarded as a confounder and therefore was adjusted for irrespective of its level of significance. 22 Analysis of vaccination effectiveness was performed based upon documented information on the immunization card. Records with missing information on immunization status were excluded from the analysis. The effectiveness of Hib vaccine was estimated as 1 minus adjusted OR. 23 Vaccine effectiveness was calculated assuming 'non-vaccinated' as reference group including children with zero or a single dose of Hib vaccine (administered at age Ͻ12 months). It has been demonstrated that a single dose at under one year old is not enough to mount a protective immune response. 9, 24 The vaccinated group pooled children who received two or three doses or a single dose after 12 months. OR with 95%CI that did not include 1.0 and Pvalues Ͻ0.05 were considered statistically significant.
Results
Between May 2000 and August 2001, 643 children р2 years of age were referred for hospital admission with the diagnosis of bacterial pneumonia provided by paediatricians, taking into account the clinical and X-ray evaluation at outpatient attendance. At hospital admission, 459 (71.4%) of 643 potential cases were confirmed as radiologically definite pneumonia by two independent radiologists, following the standardized study protocol. Of 459 potential cases, 28 could not be included as cases due to the following reasons: (1) child's age outside the inclusion criteria (2-24 months) according to the birth certificate provided by parents during the household visit; (2) home address in close proximity to the municipality but outside the urban region boundaries; (3) home address not found. Then, 431 cases and 862 controls were enrolled in the case-control study. In all, 70 children had chest radiographs with interstitial infiltrate described as peribronchial thickening and tiny areas of atelectasis, though to be typical of viral infection 19 and they were excluded from the study (Figure 1) . The 431 children diagnosed with pneumonia did not develop severe disease manifestations (e.g. meningitis, septic arthritis, and epiglottitis) as checked by prospective chart review and no participant child died during the hospitalization. The majority of pneumonia cases were mild and moderate. Previous antimicrobial therapy was reported by almost 35% of the cases, with ampicillin and trimethoprim-sulphamethoxazole (TMP-SMZ) being the main antimicrobials used (Table 1) .
Of the study participants, 83.3% (1072/1287) were classified as vaccinated according to immunization card and 16.7% (215/1287) were considered unvaccinated. Ninety per cent of children who received a single dose of the Hib vaccine before 12 months of age were under 7 months of age. There was no statistically significant association between socioeconomic variables and the prevalence of Hib immunization whereas age was statistically associated with the likelihood of vaccination. According to Table 2 , only 4.5% of children attended day-care centres in the study area. Day-care attendance was the greatest risk factor associated with pneumonia cases and accounted for 9.6% of cases versus 1.6% of controls that attended day-care centres, thus this variable was dealt with as a confounder. Cases (n = 41) and controls (n = 14) that attended day-care had mean ages respectively of 15.6 (SD 4.9) and 15.3 (SD 4.5) (t test P = 0.82). Of 55 day-care attendees, 54 had received the Hib vaccine. Sex, previous flu-like illnesses, smokers at home, house ownership, and mother's education were also statistically associated with pneumonia cases. These potential confounders were included in the final CLR model. The age stratum used to compare the age distribution between cases and controls was chosen taking into account that the required number doses of Hib vaccine to be administered to infants depends on age; thus, children between 2 and 6 months should receive three doses, children between 7 and 12 months, two doses, and only one dose should be given if children are older than 12 months of age. Variables related to crowding (no. of people, no. of rooms, etc) were not statistically associated with cases and controls. For conditional OR assessment, the analysis included 427 matched sets since immunization status was missing for 4 cases, which implied the exclusion of the corresponding triplets (12 records). On univariate analysis the OR was 0.68 (95% CI: 0.45, 1.03), leading to a Hib vaccine effectiveness of 32.0% (95% CI: Ϫ3.0%, 55.0%). No covariate was found to modify the effect of the vaccination status. According to Table 3 , the OR adjusted for the confounders was 0.69 (95% CI: 0.43, Ϫ1.09), yielding an overall vaccine effectiveness on non-bactaeraemic pneumonia of 31.0% (95% CI: Ϫ9.0%, 57.0%; P = 0.11), a slight variation of the crude estimation. Non-vaccinated children were 1.5 times more likely to develop pneumonia than those who received at least two doses of vaccine or a single dose after one year, although the P-value tells us that the result was not statistically significant. The vaccine effectiveness was similar even when missing data for the exposure variable (vaccination status) was recoded as vaccinated (vaccine effectiveness = 32.0%; 95% CI: Ϫ3.0%, 55.0%) or as unvaccinated (vaccine effectiveness = 27.0%; 95% CI: Ϫ12.0%, 52.0%). In the multivariate analysis day-care attendance remained statistically significantly associated with pneumonia (adjusted OR = 7.33; 95% CI: 3.37, 15.90; P Ͻ 0.001).
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Discussion
This is the first study to assess the vaccine effectiveness of Hib conjugate vaccine in infants with radiologically confirmed pneumonia, administered under programme conditions in Brazil. In this case-control methodology the use of Hib vaccine reduced by 31% (95% CI: Ϫ9%, 57%) pneumonia cases in infants, showing the potential benefit of Hib immunization in the prevention of likely non-bacteraemic pneumonia. In a large-scale field trial conducted in the Gambia, the Hib vaccine efficacy on pneumonia was found to be 21% (95% CI: 4.6%, 34.9%) using the same radiological end-point as the present study. 9 In Chilean children, a reduction of 22% (95% CI: Ϫ7.0%, 43.0%) of radiologically confirmed pneumonia was detected in a retrospective investigation of discharge diagnoses by chart review. 11 Although the CI of the Hib vaccine effectiveness estimated in the present study includes zero, the point estimate (31%) falls within the boundaries of the previous studies reported in the literature. Thus, our findings indicate that in a clinical practice setting in Brazil, routine Hib immunization prevented pneumonia hospitalization to a degree statistically similar to that achieved by the optimal conditions of a clinical trial (vaccine efficacy) in the Gambia and the conditions after vaccine implementation in a immunization programme (VE) in Chile. In our study no child diagnosed with pneumonia developed severe invasive disease manifestations such as meningitis, septic arthritis, and epiglottitis. In the Gambia study, cases of pneumonia, meningitis, septic arthritis, and septicaemia were detected among the episodes of culture-proven invasive Hib denoting the bactaeremic pattern of the H. influenzae disease in that country. Other studies in the Gambia have confirmed the presence of H. influenzae serotype b by recovery from percutaneous lung aspirates of children with pneumonia. 25, 26 In this sense, the epidemiological profile of Hib disease in our setting could be expected to be less invasive, i.e. nonbacteraemic disease, when compared with poorer countries. 27 The diversity of the epidemiological profile of H. influenzae causing bacteraemic and non-bacteraemic pneumonia should be considered when interpreting the study findings.
We found that the greatest risk factor for pneumonia among children Ͻ2 years of age was day-care attendance, a wellestablished risk factor for pneumonia. 28 The case definition of pneumonia in children adopted by this study based upon radiographic evidence of alveolar consolidation and/or pleural effusion followed the standardized criteria proposed by the WHO for epidemiological purposes. 19 This is considered a useful indicator of pneumonia likely to be bacterial in aetiology. 11, 25, [29] [30] [31] Children with chest radiographs compatible with a viral aetiology were excluded from this study. In our study only 11 children (2.5%) out of 431 recruited cases had severe lobar consolidation with effusion, and no pericarditis was seen; these being considered indicators of disease severity. Therefore, most of our pneumonia cases were moderate or mild according to clinical evaluation and chest X-ray patterns. It would be desirable to assess the protective effect of Hib vaccination stratifying pneumonia cases by severity; however, severe cases were few, limiting the study power for such a stratified analysis. There are some possible explanations for this local epidemiological scenario where most mild and moderate pneumonia cases in children are referred for hospitalization. First, chest X-ray is available for all children with clinical signs suspicious of pneumonia who attend the paediatric ambulatory clinic within the urban area. Second, the majority of children with chest radiograph compatible with pneumonia are referred for hospitalization. Furthermore, official Medicare allows cost reimbursement for all hospitalized pneumonia (Brazilian Health Care Security System).
According to our data, 34% of children received antimicrobial treatment before hospital admission. A recent systematic review of lung tap culture including studies conducted in all six continents has shown different proportions of isolation of H. influenzae depending on the region. In South America as a whole, H. influenzae has been found to vary widely (range: 5-50%) among children with pneumonia, while in Brazil it has been recovered in up to 38% of children who had received no antibiotics prior to hospital admission. 6 Unfortunately, H. influenzae serotyping was performed in just one of these studies 7 making it difficult to evaluate the real burden of type b and non-type b H. influenzae in childhood pneumonia in Latin America.
Childhood pneumonia is not a notifiable disease and therefore lacks reliable epidemiological baseline data before Hib vaccine implementation. The before-after design was not feasible for monitoring the impact of this intervention on pneumonia in contrast to the appropriateness of this methodology for evaluating meningitis under field conditions. [32] [33] [34] In this casecontrol study we opted for matching controls by neighbourhood in order to deal in the design phase with the similar socioeconomic parameters between cases and controls related to the likelihood of getting both pneumonia and hospital admission. The selection of controls is always a crucial issue in case-control design and subject to debate, especially when assessing vaccine effectiveness. 35 Case-control studies would be ideal in a situation where factors affecting the risk of Hib disease (particularly socioeconomic status) were equally distributed in vaccinated and in unvaccinated children. This is seldom the situation, but rather poor high-risk children tend to be unvaccinated biasing in favour of vaccine effectiveness unless this is not adequately controlled for. Neighbourhood controls go some way to rectifying this problem, as neighbourhoods tend to have similar socioeconomic parameters. It is worthwhile mentioning that the study setting is a highly urbanized area where there is a complete access to health care facilities for this age group. When the study protocol was designed the Hib vaccine had just been introduced into the routine programme. A high immunization rate of around 90% was achieved in the first year of vaccine implementation. It may be difficult to predict to what extent herd immunity could affect the estimation of the Hib vaccine effectiveness in our study area. 36 Issues concerning the herd effect following implementation of Hib immunization have been highlighted in the light of the reappearance of H. influenzae b in some regions, especially in the UK. 37, 38 For instance, some authors have pointed to evidence about low or lack of herd immunity such as: (1) the presence of invasive Hib disease among unvaccinated or incompletely vaccinated children even 2 years after the introduction of the Hib vaccine into the national immunization programme in The Gambia; 39 (2) the recent published threat of Hib disease in the UK, 40 and (3) the lack of indirect effect of the vaccine after the 3-year nationwide vaccination campaign in The Netherlands. 41 In a recent review of child mortality from preventable causes, pneumonia ranks second in a shortlist of causes and is responsible for 21% of the total deaths in children under 5 years of age in low-income countries. 42 Given the current state of the interventions capable of reducing child mortality, Hib vaccine is part of the arsenal of childhood interventions with a sufficient level of evidence of reducing the burden of childhood mortality due to pneumonia. Although immunization with Hib vaccine represents an unquestionably powerful tool for reducing infant mortality in poor countries where the burden of Hib disease has been documented, the global estimated coverage of the target population for Hib immunization is 1%. 42 The ongoing studies in Lombok and Bangladesh will certainly add important insights to the impact of the Hib vaccination in less developed countries of Asia, where mortality associated with pneumonia is high. 43, 44 In conclusion, the present investigation pointed out the potential impact of Hib vaccine on community-acquired pneumonia when measured under real conditions of immunization in Brazil. Our result is similar to previous observational investigations performed within immunization programmes in South America and with the clinical trial conducted in Africa, and confirm the relevance of the Hib vaccination as part of the regular childhood immunization schedule in developing regions.
